▎药明康德共同强生（Johnson & Johnson）与Protagonist ...

据 药明康德（603259.SH） 官微7月22日消息，药明康德共同强生（Johnson & Johnson）与Protagonist Therapeutics今日宣布，已向美国FDA提交新药申请（NDA），寻求批准其在研、每日一次口服多肽疗法icotrokinra（JNJ-2113）上市， 用于治疗12岁及以上中度至重度斑块状银屑病（PsO）成人与儿科患者 ...

November 6, 2021, Shanghai – Microsoft and Johnson & Johnson, the world’s leading healthcare company, announced that they will deepen cooperation in the Chinese market, at the 4 th International ...